LQDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LQDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Liquidia's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $86.26 Mil. Liquidia's Total Assets for the quarter that ended in Mar. 2024 was $197.12 Mil. Therefore, Liquidia's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.44.
The historical rank and industry rank for Liquidia's Equity-to-Asset or its related term are showing as below:
During the past 8 years, the highest Equity to Asset Ratio of Liquidia was 0.76. The lowest was -2.27. And the median was 0.50.
The historical data trend for Liquidia's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.51 | 0.71 | 0.70 | 0.70 | 0.40 |
Liquidia Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.63 | 0.50 | 0.43 | 0.40 | 0.44 |
For the Biotechnology subindustry, Liquidia's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Liquidia's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Liquidia's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Liquidia's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 47.293 | / | 118.332 | |
= | 0.40 |
Liquidia's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 86.26 | / | 197.116 | |
= | 0.44 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (NAS:LQDA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Liquidia's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Rajeev Saggar | officer: Chief Medical Officer | 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560 |
Jason Adair | officer: V.P. Crp Dvlpmnt and Strtgy | C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560 |
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Roger Jeffs | director | |
Caligan Partners Lp | director, 10 percent owner, other: See Remarks | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Robert A Lippe | officer: Chief Operations Officer | C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
Scott Moomaw | officer: SVP, Commercial | P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709 |
Michael Kaseta | officer: Chief Financial Officer | 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4 |
Russell Schundler | officer: General Counsel | P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709 |
Arthur S Kirsch | director | 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4 |
David Edward Johnson | 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
Katherine Rielly-gauvin | director | 419 DAVIS DRIVE, MORRISVILLE NC 27560 |
Raman Singh | director | C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560 |
Joanna Horobin | director | 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142 |
Stephen M Bloch | director | 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880 |
From GuruFocus
By Value_Insider Value_Insider • 11-08-2022
By Marketwired • 07-27-2023
By Marketwired • 09-06-2023
By Value_Insider Value_Insider • 11-01-2022
By GlobeNewswire • 06-28-2023
By GuruFocus Research • 12-19-2023
By Marketwired • 06-28-2023
By Marketwired • 08-03-2023
By PurpleRose PurpleRose • 08-11-2022
By Marketwired • 10-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.